Logo

TYRA

Tyra Biosciences, Inc.

TYRA

Tyra Biosciences, Inc. • NASDAQ
$22.56 ▲ 2.41% (+0.53)
Market Cap $1.20 B
52w High $22.82
52w Low $6.42
Dividend Yield 0%
P/E -12
Volume 273.31K
Outstanding Shares 53.37M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $32.944M ▲ $-29.868M ▼ 0% $-0.5 ▼ $-29.737M ▲
Q2-2025 $0 $31.452M ▼ $-28.098M ▲ 0% $-0.47 $-31.312M ▲
Q1-2025 $0 $31.85M ▲ $-28.147M ▼ 0% $-0.47 ▼ $-31.707M ▼
Q4-2024 $0 $29.744M ▲ $-25.571M ▼ 0% $-0.43 ▼ $-29.6M ▼
Q3-2024 $0 $28.604M $-24.016M 0% $-0.41 $-28.477M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $274.924M ▼ $301.851M ▼ $21.342M ▲ $280.509M ▼
Q2-2025 $296.271M ▼ $321.499M ▼ $19.352M ▼ $302.147M ▼
Q1-2025 $318.943M ▼ $343.476M ▼ $19.942M ▼ $323.534M ▼
Q4-2024 $341.441M ▼ $363.558M ▼ $20.407M ▲ $343.151M ▼
Q3-2024 $360.13M $380.592M $18.304M $362.288M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-29.868M ▼ $-22.38M ▲ $-14.806M ▼ $647K ▲ $-36.539M ▼ $-22.419M ▲
Q2-2025 $-28.098M ▲ $-23.68M ▲ $20.866M ▼ $583K ▼ $-2.231M ▼ $-23.711M ▲
Q1-2025 $-28.147M ▼ $-25.458M ▼ $32.026M ▲ $2.187M ▲ $8.755M ▲ $-25.472M ▼
Q4-2024 $-25.571M ▼ $-19.59M ▼ $6.958M ▼ $706K ▼ $-11.926M ▼ $-19.596M ▼
Q3-2024 $-24.016M $-17.898M $21.557M $743K $4.402M $-17.95M

Five-Year Company Overview

Income Statement

Income Statement Tyra is still a pure R&D story with no product sales yet, so its income statement is all about research spending and operating losses. Losses have grown steadily as the company has ramped up clinical trials and expanded its pipeline, which is typical for a young biotech in this phase. The pattern shows a controlled but consistent increase in expenses over time, rather than sudden spikes, suggesting deliberate scaling of operations rather than erratic cost behavior. Because there is no revenue to offset these costs, the company will likely remain loss‑making for several years, and future results will be driven almost entirely by how fast R&D and overhead spending grow as programs advance.

Balance Sheet

Balance Sheet The balance sheet looks like that of a clinical‑stage biotech: a sizable cash position compared with the overall size of the company, very little debt, and equity funded mostly through past capital raises. Assets are heavily tilted toward cash and equivalents, which is what you want for funding long clinical programs. Reported equity dipped into negative territory in an earlier year but has since been rebuilt, reflecting subsequent financings and balance sheet cleanup. The current structure is conservative, with minimal leverage and a cushion of cash, but inherently dependent on capital markets or partnerships over time, since there is no operating income to replenish resources yet.

Cash Flow

Cash Flow Cash flows show a consistent outflow from operating activities driven by research, clinical work, and corporate costs. There is essentially no spending on heavy equipment or facilities, so almost all cash burn is tied to people, trials, and external R&D. Free cash flow is negative and closely tracks operating cash outflow, which is what you expect at this stage. The key question for the future is how long the current cash can fund this burn rate; management has indicated a multi‑year runway, but that depends on keeping spending disciplined and on how quickly programs move into more expensive late‑stage trials.

Competitive Edge

Competitive Edge Tyra operates in a very competitive part of oncology, where several large pharma companies already have approved FGFR inhibitors or advanced candidates. Its edge comes from a clear focus on drug resistance—trying to work where first‑generation drugs fail—and from its proprietary SNÅP platform, which is designed to quickly design and refine highly selective inhibitors. The company’s specialization in FGFR biology and resistance mechanisms gives it a distinct niche, particularly in second‑line settings where options are limited. However, its smaller size and earlier stage relative to big pharma peers mean it needs strong clinical data and possibly partnerships to fully convert this scientific edge into a durable market position.

Innovation and R&D

Innovation and R&D Innovation is the core of Tyra’s story. The SNÅP platform is built to rapidly generate structural insights that guide the design of next‑generation kinase inhibitors, with a strong emphasis on anticipating and overcoming resistance mutations. The pipeline reflects this: the lead drug dabogratinib targets FGFR3‑driven cancers that have failed earlier FGFR therapies, and the company is extending its use into multiple tumor types and even into achondroplasia, a genetic bone growth disorder. Additional programs like TYRA‑200 and TYRA‑430 broaden coverage across FGFR family targets, and there are early moves toward other kinases such as RET. Overall R&D is focused, mechanism‑driven, and tightly linked to the platform’s strengths, but success still depends on clinical trial outcomes, which are inherently uncertain.

Summary

Tyra is a classic clinical‑stage oncology biotech: no revenue yet, intentional and rising R&D‑driven losses, and a balance sheet centered on cash raised from investors rather than from operations. Financially, it appears reasonably conservative, with low debt and a multi‑year cash runway, but it is reliant on continued access to capital or partnerships until products reach the market. Strategically, the company is trying to differentiate itself in a crowded FGFR space by focusing on acquired resistance and by leveraging its SNÅP platform to design more selective, durable inhibitors. The pipeline is still in relatively early and mid‑stage development, so the story is high‑risk, high‑uncertainty, and highly dependent on clinical readouts over the next few years. If its approach to resistance and precision design translates into strong trial data, Tyra’s scientific platform could support a broader franchise beyond its initial cancer indications.

NEWS

November 12, 2025 · 4:05 PM UTC

Tyra Biosciences Announces Participation at Upcoming Investor Events

Read more

November 5, 2025 · 4:05 PM UTC

Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

Read more